Human Immunology Biosciences

Executive Summary

Human Immunology Biosciences (HI-Bio) is a private, preclinical-stage biotechnology company headquartered in San Diego, CA, focused on discovering and developing novel antibody therapeutics that modulate the human immune system. Founded in 2019, the company has raised approximately $120 million to advance its pipeline targeting autoimmune diseases, inflammation, and immuno-oncology. HI-Bio leverages deep immunology expertise to create precise, effective treatments with improved safety profiles. Currently in the preclinical stage, the company's lead programs are expected to enter IND-enabling studies in the near term. HI-Bio's approach aims to address high-unmet-need indications by targeting key immune pathways. With a strong funding base and a clear focus on immunology, the company is positioned to advance its candidates through the clinic, though the typical risks of preclinical development remain.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Submission40% success
• Q3 2026Preclinical Data Presentation at Major Conference60% success
• Q2 2026Series C Financing or Partnership Announcement50% success